|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Phospholipase A2 Inhibitors inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Phospholipase A2 Inhibitors inhibits the reaction [IL1B protein results in increased expression of MMP2 mRNA]; Phospholipase A2 Inhibitors inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Phospholipase A2 Inhibitors inhibits the reaction [IL1B protein results in increased expression of MMP9 mRNA]; Phospholipase A2 Inhibitors inhibits the reaction [IL1B protein results in increased expression of PLA2G2A mRNA]; Phospholipase A2 Inhibitors inhibits the reaction [IL1B protein results in increased secretion of MMP1 protein]; Phospholipase A2 Inhibitors inhibits the reaction [IL1B protein results in increased secretion of MMP2 protein]; Phospholipase A2 Inhibitors inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; Phospholipase A2 Inhibitors inhibits the reaction [IL1B protein results in increased secretion of MMP9 protein]; Phospholipase A2 Inhibitors inhibits the reaction [IL1B protein results in increased secretion of PLA2G2A protein] |
CTD |
PMID:19765281 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
decreases secretion |
EXP |
Phospholipase A2 Inhibitors results in decreased secretion of IL6 protein |
CTD |
PMID:19765281 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Mmp1b |
matrix metallopeptidase 1b (interstitial collagenase) |
multiple interactions decreases expression |
ISO |
Phospholipase A2 Inhibitors inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Phospholipase A2 Inhibitors inhibits the reaction [IL1B protein results in increased secretion of MMP1 protein] Phospholipase A2 Inhibitors results in decreased expression of MMP1 mRNA |
CTD |
PMID:19765281 |
|
NCBI chr 9:7,367,670...7,388,026
Ensembl chr 9:7,368,239...7,388,047
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases expression |
ISO |
Phospholipase A2 Inhibitors inhibits the reaction [IL1B protein results in increased expression of MMP2 mRNA]; Phospholipase A2 Inhibitors inhibits the reaction [IL1B protein results in increased secretion of MMP2 protein] Phospholipase A2 Inhibitors results in decreased expression of MMP2 mRNA |
CTD |
PMID:19765281 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions decreases expression |
ISO |
Phospholipase A2 Inhibitors inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Phospholipase A2 Inhibitors inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein] Phospholipase A2 Inhibitors results in decreased expression of MMP3 mRNA |
CTD |
PMID:19765281 |
|
NCBI chr 9:7,445,845...7,455,975
Ensembl chr 9:7,445,822...7,455,975
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
ISO |
Phospholipase A2 Inhibitors inhibits the reaction [IL1B protein results in increased expression of MMP9 mRNA]; Phospholipase A2 Inhibitors inhibits the reaction [IL1B protein results in increased secretion of MMP9 protein] Phospholipase A2 Inhibitors results in decreased expression of MMP9 mRNA |
CTD |
PMID:19765281 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Pla2g2a |
phospholipase A2, group IIA (platelets, synovial fluid) |
multiple interactions decreases expression |
ISO |
Phospholipase A2 Inhibitors inhibits the reaction [IL1B protein results in increased expression of PLA2G2A mRNA]; Phospholipase A2 Inhibitors inhibits the reaction [IL1B protein results in increased secretion of PLA2G2A protein] Phospholipase A2 Inhibitors results in decreased expression of PLA2G2A mRNA |
CTD |
PMID:19765281 |
|
NCBI chr 4:138,559,168...138,562,500
Ensembl chr 4:138,559,171...138,562,497
|
|
G |
Tnf |
tumor necrosis factor |
decreases secretion |
ISO |
Phospholipase A2 Inhibitors results in decreased secretion of TNF protein |
CTD |
PMID:19765281 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [AGT protein results in increased abundance of Epoprostenol] |
CTD |
PMID:14613874 |
|
NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions |
ISO EXP |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CXCL8 mRNA] arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CXCL15 mRNA] |
CTD |
PMID:18938131 PMID:19063610 PMID:19162293 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:18938131 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
multiple interactions |
EXP |
arachidonyltrifluoromethane inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid] |
CTD |
PMID:19014389 |
|
NCBI chr15:54,702,297...54,816,284
Ensembl chr15:54,702,297...54,816,288
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] |
CTD |
PMID:29642561 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Ins1 |
insulin I |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [BL 11282 promotes the reaction [Glucose results in increased secretion of INS1 protein]] |
CTD |
PMID:17922229 |
|
NCBI chr19:52,252,735...52,253,453
Ensembl chr19:52,252,735...52,253,914
|
|
G |
Ins2 |
insulin II |
increases secretion multiple interactions |
ISO |
arachidonyltrifluoromethane results in increased secretion of INS protein arachidonyltrifluoromethane inhibits the reaction [Glucose results in increased secretion of INS protein] |
CTD |
PMID:17192482 |
|
NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118
|
|
G |
Lep |
leptin |
multiple interactions |
EXP |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of LEP mRNA] |
CTD |
PMID:19063610 |
|
NCBI chr 6:29,060,220...29,073,875
Ensembl chr 6:29,060,219...29,073,876
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:15231676 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:15231676 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Nrg1 |
neuregulin 1 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK1 protein]; arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:15231676 |
|
NCBI chr 8:32,299,493...33,381,858
Ensembl chr 8:32,304,579...33,374,825 Ensembl chr 8:32,304,579...33,374,825
|
|
G |
Pla2g4a |
phospholipase A2, group IVA (cytosolic, calcium-dependent) |
multiple interactions |
EXP ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of PLA2G4A protein] arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G4A mRNA] |
CTD |
PMID:18938131 PMID:19063610 PMID:19162293 |
|
NCBI chr 1:149,705,369...149,837,041
Ensembl chr 1:149,705,369...149,837,041
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions |
EXP |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPARG mRNA] |
CTD |
PMID:19063610 |
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of PTGS2 protein]; arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]; arachidonyltrifluoromethane promotes the reaction [Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]] |
CTD |
PMID:18938131 PMID:19063610 PMID:19162293 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
S100a11 |
S100 calcium binding protein A11 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [S100A11 mutant form results in increased susceptibility to Cisplatin]; arachidonyltrifluoromethane inhibits the reaction [S100A11 mutant form results in increased susceptibility to oxaliplatin] |
CTD |
PMID:25940438 |
|
NCBI chr 3:93,427,803...93,433,595
Ensembl chr 3:93,427,795...93,433,594
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
EXP |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SOCS3 mRNA] |
CTD |
PMID:19063610 |
|
NCBI chr11:117,856,905...117,860,192
Ensembl chr11:117,856,905...117,860,873
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [TNF protein results in increased expression of SOD2] |
CTD |
PMID:11264281 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [TNF protein results in increased expression of SOD2] |
CTD |
PMID:11264281 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO EXP |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA] arachidonyltrifluoromethane promotes the reaction [Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA]] |
CTD |
PMID:19063610 PMID:19162293 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
|
G |
2310047C04Rik |
RIKEN cDNA 2310047C04 gene |
increases expression |
ISO |
Berberine results in increased expression of DZIP3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr16:48,744,591...48,814,505
Ensembl chr16:48,744,595...48,814,528
|
|
G |
4921524K10Rik |
RIKEN cDNA 4921524K10 gene |
increases expression |
ISO |
Berberine results in increased expression of SETD2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 9:110,361,368...110,447,703
Ensembl chr 9:110,361,665...110,447,701
|
|
G |
Abca1 |
ATP-binding cassette, sub-family A member 1 |
increases expression |
EXP |
berberine increases expression of abca1 protein in mouse liver and human hepatocytes |
RGD |
PMID:29505790 |
RGD:19165131 |
NCBI chr 4:53,030,789...53,159,988
Ensembl chr 4:53,030,787...53,159,895
|
|
G |
Abcb1a |
ATP-binding cassette, sub-family B member 1A |
increases expression |
ISO |
Berberine results in increased expression of ABCB1A mRNA |
CTD |
PMID:20410605 |
|
NCBI chr 5:8,617,091...8,798,575
Ensembl chr 5:8,710,077...8,798,575
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
increases expression |
ISO |
Berberine results in increased expression of ABCB1B mRNA |
CTD |
PMID:20410605 |
|
NCBI chr 5:8,848,147...8,916,314
Ensembl chr 5:8,848,147...8,916,315
|
|
G |
Acadm |
acyl-Coenzyme A dehydrogenase, medium chain |
multiple interactions |
EXP |
Berberine inhibits the reaction [Ethanol results in decreased expression of ACADM mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr 3:153,627,990...153,650,280
Ensembl chr 3:153,627,994...153,650,269
|
|
G |
Acan |
aggrecan |
decreases expression |
ISO |
Berberine results in decreased expression of ACAN mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 7:78,702,974...78,764,847
Ensembl chr 7:78,703,231...78,764,847
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions decreases activity |
ISO |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA]; Berberine inhibits the reaction [acetamiprid results in increased activity of ACHE protein] Berberine results in decreased activity of ACHE protein |
CTD |
PMID:29170048 PMID:33844597 PMID:37350525 |
|
NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728
|
|
G |
Acox1 |
acyl-Coenzyme A oxidase 1, palmitoyl |
multiple interactions |
EXP |
Berberine inhibits the reaction [Ethanol results in decreased expression of ACOX1 mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr11:116,062,714...116,089,605
Ensembl chr11:116,062,714...116,089,871
|
|
G |
Acta2 |
actin alpha 2, smooth muscle, aorta |
decreases expression multiple interactions |
ISO EXP |
Berberine results in decreased expression of ACTA2 protein Berberine inhibits the reaction [Particulate Matter results in increased expression of ACTA2 mRNA] |
CTD |
PMID:17973934 PMID:37839514 |
|
NCBI chr19:34,217,736...34,232,985
Ensembl chr19:34,218,490...34,232,990
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
EXP |
Berberine inhibits the reaction [Clozapine results in increased expression of ADIPOQ mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of ADIPOQ mRNA] |
CTD |
PMID:20564506 |
|
NCBI chr16:22,965,286...22,976,718
Ensembl chr16:22,965,286...22,976,778
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions |
ISO |
Berberine inhibits the reaction [Bortezomib results in increased expression of AGER mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr17:34,816,545...34,819,911
Ensembl chr17:34,816,836...34,819,910
|
|
G |
Ahr |
aryl-hydrocarbon receptor |
increases activity |
ISO |
Berberine results in increased activity of AHR protein |
CTD |
PMID:16046213 |
|
NCBI chr12:35,547,978...35,584,988
Ensembl chr12:35,547,973...35,585,037
|
|
G |
Akt1 |
thymoma viral proto-oncogene 1 |
multiple interactions decreases phosphorylation increases phosphorylation |
ISO |
Berberine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein] Berberine results in decreased phosphorylation of AKT1 protein Berberine inhibits the reaction [Thioacetamide results in increased phosphorylation of AKT1 protein] Berberine results in increased phosphorylation of AKT1 protein |
CTD |
PMID:23954465 PMID:30138605 PMID:33325633 |
|
NCBI chr12:112,620,260...112,641,266
Ensembl chr12:112,620,255...112,641,318
|
|
G |
Akt2 |
thymoma viral proto-oncogene 2 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Dexamethasone results in decreased expression of AKT2 mRNA] |
CTD |
PMID:20462044 |
|
NCBI chr 7:27,290,977...27,340,251
Ensembl chr 7:27,290,977...27,340,251
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
Berberine inhibits the reaction [Thioacetamide results in decreased expression of ALB protein] |
CTD |
PMID:30138605 |
|
NCBI chr 5:90,608,729...90,624,461
Ensembl chr 5:90,608,756...90,624,461
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of APP mRNA] |
CTD |
PMID:29170048 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Aurkb |
aurora kinase B |
decreases expression |
ISO |
Berberine results in decreased expression of AURKB mRNA |
CTD |
PMID:27311644 |
|
NCBI chr11:68,936,477...68,942,490
Ensembl chr11:68,936,473...68,942,490
|
|
G |
Aurkc |
aurora kinase C |
increases expression |
ISO |
Berberine results in increased expression of AURKC mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 7:6,998,346...7,006,090
Ensembl chr 7:6,998,299...7,006,090
|
|
G |
Bax |
BCL2-associated X protein |
multiple interactions increases expression |
ISO |
[Berberine co-treated with Thioacetamide] results in increased expression of BAX mRNA; Berberine inhibits the reaction [Chlorpyrifos results in increased expression of BAX mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of BAX protein] Berberine results in increased expression of BAX mRNA; Berberine results in increased expression of BAX protein [Berberine co-treated with Cisplatin] results in increased expression of BAX protein; [Berberine co-treated with Niacinamide] results in increased expression of BAX protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased expression of BAX protein]; SRT1720 inhibits the reaction [Berberine results in increased expression of BAX protein] |
CTD |
PMID:16505103 PMID:20656010 PMID:25600690 PMID:26712469 PMID:30138605 PMID:35439518 PMID:36070022 More...
|
|
NCBI chr 7:45,111,124...45,116,332
Ensembl chr 7:45,111,121...45,116,322
|
|
G |
Bbc3 |
BCL2 binding component 3 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of BBC3 mRNA [Berberine co-treated with Niacinamide] results in increased expression of BBC3 mRNA |
CTD |
PMID:26712469 |
|
NCBI chr 7:16,042,307...16,052,130
Ensembl chr 7:16,042,318...16,052,130
|
|
G |
Bcl2 |
B cell leukemia/lymphoma 2 |
decreases expression increases expression multiple interactions |
ISO |
Berberine results in decreased expression of BCL2 mRNA; Berberine results in decreased expression of BCL2 protein Berberine results in increased expression of BCL2 protein Berberine inhibits the reaction [Chlorpyrifos results in decreased expression of BCL2 mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of BCL2 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of BCL2 mRNA] [Berberine co-treated with Cisplatin] results in decreased expression of BCL2 protein; [Berberine co-treated with Niacinamide] results in decreased expression of BCL2 protein; Berberine inhibits the reaction [Glucose results in decreased expression of BCL2 protein] |
CTD |
PMID:16505103 PMID:20656010 PMID:23954465 PMID:24751971 PMID:25600690 PMID:26712469 PMID:30138605 PMID:35439518 PMID:36070022 More...
|
|
NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004
|
|
G |
Bcl2l1 |
BCL2-like 1 |
decreases expression |
ISO |
Berberine results in decreased expression of BCL2L1 protein |
CTD |
PMID:16505103 |
|
NCBI chr 2:152,600,652...152,673,632
Ensembl chr 2:152,622,588...152,673,648
|
|
G |
Bcl2l11 |
BCL2 like 11 |
multiple interactions increases expression |
ISO |
[Berberine co-treated with Niacinamide] results in increased expression of BCL2L11 mRNA Berberine results in increased expression of BCL2L11 mRNA |
CTD |
PMID:26712469 |
|
NCBI chr 2:127,967,958...128,004,467
Ensembl chr 2:127,967,958...128,004,467
|
|
G |
Becn1 |
beclin 1, autophagy related |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Chlorpyrifos results in decreased expression of BECN1 mRNA] Berberine promotes the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BECN1 protein] |
CTD |
PMID:35439518 PMID:38705399 |
|
NCBI chr11:101,179,084...101,193,112
Ensembl chr11:101,176,778...101,193,112
|
|
G |
Bglap |
bone gamma carboxyglutamate protein |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of BGLAP mRNA; Berberine results in increased expression of BGLAP protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of BGLAP protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of BGLAP protein] |
CTD |
PMID:26478571 |
|
NCBI chr 3:88,290,802...88,291,773
Ensembl chr 3:88,290,808...88,291,771
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
affects binding |
ISO |
Berberine binds to BIRC5 promoter |
CTD |
PMID:17968851 |
|
NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569
|
|
G |
Bnip3 |
BCL2/adenovirus E1B interacting protein 3 |
multiple interactions increases expression |
ISO EXP |
[Cisplatin co-treated with Berberine] results in increased expression of BNIP3 protein Berberine promotes the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BNIP3 protein] Berberine results in increased expression of BNIP3 protein |
CTD |
PMID:36070022 PMID:38705399 |
|
NCBI chr 7:138,492,565...138,511,235
Ensembl chr 7:138,492,565...138,511,248
|
|
G |
Bnip3l |
BCL2/adenovirus E1B interacting protein 3-like |
multiple interactions increases expression |
ISO |
[Cisplatin co-treated with Berberine] results in increased expression of BNIP3L protein; BNIP3L protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein] Berberine results in increased expression of BNIP3L protein |
CTD |
PMID:36070022 |
|
NCBI chr14:67,222,688...67,246,580
Ensembl chr14:67,222,688...67,246,326
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of and results in increased cleavage of CASP1 protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CASP1 mRNA] |
CTD |
PMID:38705399 |
|
NCBI chr 9:5,298,517...5,307,281
Ensembl chr 9:5,298,508...5,307,290
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases cleavage increases expression |
ISO EXP |
[Berberine co-treated with Cisplatin] results in increased cleavage of CASP3 protein; [Berberine co-treated with Niacinamide] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased cleavage of CASP3 protein]; Berberine results in increased cleavage of and results in increased activity of CASP3 protein Berberine inhibits the reaction [Particulate Matter results in increased expression of CASP3 protein] Berberine increases activity of CASP3 protein in colon epithelial cells Berberine results in increased cleavage of CASP3 protein [Berberine co-treated with Thioacetamide] results in increased expression of CASP3 mRNA; Berberine inhibits the reaction [Chlorpyrifos results in increased expression of CASP3 mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in increased activity of CASP3 protein]; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of CASP3 mRNA] Berberine results in increased activity of CASP3 protein Berberine results in increased expression of CASP3 mRNA |
CTD RGD |
PMID:16505103 PMID:20656010 PMID:25600690 PMID:26712469 PMID:30138605 PMID:33460233 PMID:35439518 PMID:36070022 PMID:37839514 PMID:29564000 More...
|
RGD:152995489 |
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
Berberine results in increased activity of CASP8 protein |
CTD |
PMID:20656010 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Casp9 |
caspase 9 |
increases cleavage multiple interactions |
ISO EXP |
Berberine results in increased cleavage of CASP9 protein Berberine inhibits the reaction [Particulate Matter results in increased expression of CASP9 protein] [Berberine co-treated with Thioacetamide] results in increased expression of CASP9 mRNA [Berberine co-treated with Niacinamide] results in increased cleavage of CASP9 protein |
CTD |
PMID:16505103 PMID:26712469 PMID:30138605 PMID:37839514 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Cat |
catalase |
multiple interactions |
ISO EXP |
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the activity of CAT protein]; Berberine inhibits the reaction [acetamiprid results in decreased activity of CAT protein]; Berberine inhibits the reaction [Bortezomib results in decreased expression of CAT protein]; Berberine inhibits the reaction [Chlorpyrifos results in decreased activity of CAT protein]; Berberine inhibits the reaction [Mercuric Chloride results in decreased activity of CAT protein]; Berberine inhibits the reaction [Thioacetamide results in decreased activity of CAT protein] Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of CAT protein] |
CTD |
PMID:20828602 PMID:24751971 PMID:25600690 PMID:30138605 PMID:33460233 PMID:35121005 PMID:35439518 PMID:35691465 PMID:37350525 PMID:37839514 More...
|
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [TNF protein results in increased secretion of CCL2 protein] Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CCL2 mRNA] |
CTD |
PMID:16391493 PMID:35691465 PMID:38705399 |
|
NCBI chr11:81,926,403...81,928,278
Ensembl chr11:81,926,397...81,928,279
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression multiple interactions |
ISO |
Berberine results in decreased expression of CCND1 protein Berberine inhibits the reaction [CDK4 mRNA binds to CCND1 mRNA] |
CTD |
PMID:16505103 PMID:33325633 PMID:36822301 |
|
NCBI chr 7:144,483,668...144,493,568
Ensembl chr 7:144,483,668...144,493,662
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression |
ISO |
Berberine results in decreased expression of CCND2 protein |
CTD |
PMID:16505103 |
|
NCBI chr 6:127,102,125...127,131,913
Ensembl chr 6:127,102,125...127,129,156
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
Berberine results in decreased expression of CCNE1 protein |
CTD |
PMID:16505103 |
|
NCBI chr 7:37,797,409...37,806,915
Ensembl chr 7:37,797,409...37,806,959
|
|
G |
Ccnt1 |
cyclin T1 |
multiple interactions |
ISO |
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CCNT1 mRNA]; Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CCNT1 protein] |
CTD |
PMID:20828602 |
|
NCBI chr15:98,436,570...98,468,340
Ensembl chr15:98,436,570...98,468,804
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions increases expression |
ISO EXP |
15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of CD36 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Berberine results in increased expression of CD36 protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of CD36 mRNA]; Berberine results in increased expression of and affects the localization of CD36 protein; CEBPB protein promotes the reaction [Berberine results in increased expression of CD36 mRNA] Berberine results in increased expression of CD36 mRNA; Berberine results in increased expression of CD36 protein |
CTD |
PMID:28038998 PMID:29408570 |
|
NCBI chr 5:17,986,680...18,093,828
Ensembl chr 5:17,986,688...18,093,799
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Particulate Matter results in decreased expression of CDH1 mRNA] |
CTD |
PMID:37839514 |
|
NCBI chr 8:107,329,982...107,396,879
Ensembl chr 8:107,329,983...107,396,878
|
|
G |
Cdh2 |
cadherin 2 |
decreases expression |
ISO |
Berberine results in decreased expression of CDH2 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr18:16,721,934...16,942,303
Ensembl chr18:16,721,934...16,942,303
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
Berberine results in decreased expression of CDK2 protein |
CTD |
PMID:16505103 |
|
NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900
|
|
G |
Cdk4 |
cyclin dependent kinase 4 |
decreases expression multiple interactions |
ISO |
Berberine results in decreased expression of CDK4 protein Berberine inhibits the reaction [CDK4 mRNA binds to CCND1 mRNA] |
CTD |
PMID:16505103 PMID:36822301 |
|
NCBI chr10:126,899,404...126,903,157
Ensembl chr10:126,899,403...126,903,789
|
|
G |
Cdk6 |
cyclin dependent kinase 6 |
decreases expression |
ISO |
Berberine results in decreased expression of CDK6 protein |
CTD |
PMID:16505103 |
|
NCBI chr 5:3,391,004...3,581,008
Ensembl chr 5:3,391,485...3,581,008
|
|
G |
Cdk9 |
cyclin dependent kinase 9 |
multiple interactions |
ISO |
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CDK9 mRNA]; Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CDK9 protein] |
CTD |
PMID:20828602 |
|
NCBI chr 2:32,595,794...32,608,098
Ensembl chr 2:32,595,796...32,603,088
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
increases expression |
ISO |
Berberine results in increased expression of CDKN1A protein |
CTD |
PMID:16505103 PMID:23747414 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cdkn1b |
cyclin dependent kinase inhibitor 1B |
increases expression |
ISO |
Berberine results in increased expression of CDKN1B protein |
CTD |
PMID:16505103 |
|
NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476
|
|
G |
Cdkn1c |
cyclin dependent kinase inhibitor 1C |
increases expression |
ISO |
Berberine results in increased expression of CDKN1C mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 7:143,012,076...143,014,735
Ensembl chr 7:143,012,076...143,014,787
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions decreases expression |
EXP ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA protein]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA protein] Berberine results in decreased expression of CEBPA mRNA; Berberine results in decreased expression of CEBPA protein |
CTD |
PMID:20564506 PMID:26478571 PMID:37511356 |
|
NCBI chr 7:34,818,718...34,821,353
Ensembl chr 7:34,818,718...34,821,353
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
affects phosphorylation increases expression multiple interactions |
EXP ISO |
Berberine affects the phosphorylation of CEBPB protein Berberine results in increased expression of CEBPB mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Berberine results in increased phosphorylation of CEBPB protein]; CEBPB protein promotes the reaction [Berberine results in increased expression of CD36 mRNA] |
CTD |
PMID:28038998 |
|
NCBI chr 2:167,530,835...167,532,352
Ensembl chr 2:167,530,835...167,532,338
|
|
G |
Chek1 |
checkpoint kinase 1 |
increases expression |
ISO |
Berberine results in increased expression of CHEK1 protein modified form |
CTD |
PMID:23747414 |
|
NCBI chr 9:36,619,935...36,637,897
Ensembl chr 9:36,619,778...36,638,361
|
|
G |
Chek2 |
checkpoint kinase 2 |
increases expression |
ISO |
Berberine results in increased expression of CHEK2 protein modified form |
CTD |
PMID:23747414 |
|
NCBI chr 5:110,987,668...111,022,006
Ensembl chr 5:110,987,845...111,022,011
|
|
G |
Col10a1 |
collagen, type X, alpha 1 |
increases expression |
ISO |
Berberine results in increased expression of COL10A1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr10:34,265,977...34,273,081
Ensembl chr10:34,265,977...34,273,081
|
|
G |
Col1a1 |
collagen, type I, alpha 1 |
increases expression multiple interactions |
ISO EXP |
Berberine results in increased expression of COL1A1 mRNA Berberine inhibits the reaction [Particulate Matter results in increased expression of COL1A1 mRNA] |
CTD |
PMID:26478571 PMID:37839514 |
|
NCBI chr11:94,827,050...94,843,868
Ensembl chr11:94,827,050...94,843,868
|
|
G |
Col2a1 |
collagen, type II, alpha 1 |
decreases expression |
ISO |
Berberine results in decreased expression of COL2A1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr15:97,873,483...97,902,525
Ensembl chr15:97,873,483...97,902,576
|
|
G |
Col3a1 |
collagen, type III, alpha 1 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Particulate Matter results in increased expression of COL3A1 mRNA] |
CTD |
PMID:37839514 |
|
NCBI chr 1:45,350,698...45,388,866
Ensembl chr 1:45,350,698...45,388,866
|
|
G |
Cox4i1 |
cytochrome c oxidase subunit 4I1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [acetamiprid results in decreased expression of COX4I1 mRNA] |
CTD |
PMID:37350525 |
|
NCBI chr 8:121,394,964...121,400,948
Ensembl chr 8:121,394,961...121,400,946
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1a, liver |
multiple interactions |
EXP |
Berberine inhibits the reaction [Ethanol results in decreased expression of CPT1A mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr19:3,372,328...3,435,735
Ensembl chr19:3,372,334...3,435,733
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Bortezomib results in decreased expression of CREB1 protein] |
CTD |
PMID:35121005 |
|
NCBI chr 1:64,571,963...64,643,707
Ensembl chr 1:64,571,804...64,643,707
|
|
G |
Crebbp |
CREB binding protein |
increases expression |
ISO |
Berberine results in increased expression of CREBBP mRNA |
CTD |
PMID:27311644 |
|
NCBI chr16:3,899,198...4,031,864
Ensembl chr16:3,899,192...4,031,861
|
|
G |
Cst3 |
cystatin C |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CST3 protein] |
CTD |
PMID:38705399 |
|
NCBI chr 2:148,713,642...148,717,432
Ensembl chr 2:148,713,642...148,717,612
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of CTNNB1 protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of BGLAP protein]; CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of SPP1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of CTNNB1 protein] |
CTD |
PMID:26478571 |
|
NCBI chr 9:120,762,466...120,789,573
Ensembl chr 9:120,758,282...120,789,573
|
|
G |
Ctsd |
cathepsin D |
decreases cleavage multiple interactions |
ISO |
Berberine results in decreased cleavage of CTSD protein GSK2795039 affects the reaction [Berberine results in decreased cleavage of CTSD protein] |
CTD |
PMID:36070022 |
|
NCBI chr 7:141,929,647...141,941,564
Ensembl chr 7:141,929,648...141,941,775
|
|
G |
Ctsl |
cathepsin L |
decreases cleavage multiple interactions |
ISO |
Berberine results in decreased cleavage of CTSL protein Acetylcysteine inhibits the reaction [Berberine results in decreased cleavage of CTSL protein]; GSK2795039 affects the reaction [Berberine results in decreased cleavage of CTSL protein] |
CTD |
PMID:36070022 |
|
NCBI chr13:64,509,704...64,518,586
Ensembl chr13:64,507,151...64,518,704
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions |
ISO |
Berberine inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein]; Berberine inhibits the reaction [Mustard Gas results in increased secretion of CXCL8 protein]; Berberine inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein] |
CTD |
PMID:16391493 PMID:28916288 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cybb |
cytochrome b-245, beta polypeptide |
multiple interactions |
ISO |
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF1 protein]; Berberine promotes the reaction [CYBB protein binds to NCF2 protein]; Berberine promotes the reaction [CYBB protein binds to RAC2 protein] |
CTD |
PMID:36070022 |
|
NCBI chr X:9,301,493...9,354,005
Ensembl chr X:9,301,491...9,354,010
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization multiple interactions |
ISO |
Berberine affects the localization of CYCS protein [Berberine co-treated with Cisplatin] results in increased expression of CYCS protein |
CTD |
PMID:16505103 PMID:36070022 |
|
NCBI chr 6:50,539,543...50,543,549
Ensembl chr 6:50,539,543...50,543,518
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Dexamethasone results in increased expression of CYP17A1 mRNA] |
CTD |
PMID:20462044 |
|
NCBI chr19:46,655,604...46,661,439
Ensembl chr19:46,655,604...46,661,611
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity increases expression multiple interactions |
ISO EXP |
Berberine results in decreased activity of CYP1A1 protein Berberine results in increased expression of CYP1A1 mRNA Berberine inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:16046213 PMID:22342832 PMID:24583342 |
|
NCBI chr 9:57,595,211...57,611,107
Ensembl chr 9:57,595,211...57,611,107
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
Berberine inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A2 mRNA] |
CTD |
PMID:22342832 |
|
NCBI chr 9:57,584,220...57,590,938
Ensembl chr 9:57,584,220...57,590,986
|
|
G |
Cyp2b10 |
cytochrome P450, family 2, subfamily b, polypeptide 10 |
multiple interactions increases expression |
EXP |
Berberine inhibits the reaction [Streptozocin results in increased expression of CYP2B10 mRNA]; Berberine promotes the reaction [Phenobarbital results in increased expression of CYP2B10 mRNA] Berberine results in increased expression of CYP2B10 mRNA |
CTD |
PMID:22342832 |
|
NCBI chr 7:25,597,083...25,626,049
Ensembl chr 7:25,597,045...25,626,049
|
|
G |
Cyp2b9 |
cytochrome P450, family 2, subfamily b, polypeptide 9 |
multiple interactions increases expression |
EXP |
Berberine promotes the reaction [Phenobarbital results in increased expression of CYP2B9 mRNA]; Berberine promotes the reaction [Streptozocin results in increased expression of CYP2B9 mRNA] Berberine results in increased expression of CYP2B9 mRNA |
CTD |
PMID:22342832 |
|
NCBI chr 7:25,872,775...25,910,086
Ensembl chr 7:25,872,836...25,910,086
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases expression multiple interactions |
EXP |
Berberine results in decreased expression of CYP2E1 mRNA Berberine inhibits the reaction [Ethanol results in increased expression of CYP2E1 protein]; Berberine inhibits the reaction [Isoniazid results in increased expression of CYP2E1 mRNA] |
CTD |
PMID:22342832 PMID:25455889 |
|
NCBI chr 7:140,343,732...140,354,903
Ensembl chr 7:140,343,652...140,354,900
|
|
G |
Cyp3a11 |
cytochrome P450, family 3, subfamily a, polypeptide 11 |
multiple interactions decreases expression |
EXP |
Berberine inhibits the reaction [Dexamethasone results in increased expression of CYP3A11 mRNA]; Berberine inhibits the reaction [Streptozocin results in increased expression of CYP3A11 mRNA] Berberine results in decreased expression of CYP3A11 mRNA |
CTD |
PMID:22342832 |
|
NCBI chr 5:145,791,417...145,816,664
Ensembl chr 5:145,791,236...145,816,774
|
|
G |
Cyp4a10 |
cytochrome P450, family 4, subfamily a, polypeptide 10 |
multiple interactions decreases expression |
EXP |
Berberine inhibits the reaction [Clofibrate results in increased expression of CYP4A10 mRNA]; Berberine inhibits the reaction [Streptozocin results in increased expression of CYP4A10 mRNA] Berberine results in decreased expression of CYP4A10 mRNA |
CTD |
PMID:22342832 |
|
NCBI chr 4:115,375,484...115,390,846
Ensembl chr 4:115,375,461...115,390,846
|
|
G |
Cyp4a14 |
cytochrome P450, family 4, subfamily a, polypeptide 14 |
multiple interactions decreases expression |
EXP |
Berberine inhibits the reaction [Clofibrate results in increased expression of CYP4A14 mRNA]; Berberine inhibits the reaction [Streptozocin results in increased expression of CYP4A14 mRNA] Berberine results in decreased expression of CYP4A14 mRNA |
CTD |
PMID:22342832 |
|
NCBI chr 4:115,343,397...115,353,355
Ensembl chr 4:115,343,397...115,353,339
|
|
G |
D19Ucla1 |
DNA segment, Chr 19, University of California at Los Angeles 1 |
increases expression |
ISO |
Berberine increases expression of PDCD4 protein in colon epithelial cells |
RGD |
PMID:29564000 |
RGD:152995489 |
NCBI chr19:53,880,662...53,926,024
Ensembl chr19:53,880,662...53,918,291
|
|
G |
D4Ertd478e |
DNA segment, Chr 4, ERATO Doi 478, expressed |
increases expression |
ISO |
Berberine results in increased expression of KDM1A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 4:136,277,844...136,330,127
Ensembl chr 4:136,277,851...136,330,034
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
multiple interactions |
ISO |
DKK1 protein inhibits the reaction [Berberine results in increased expression of BGLAP protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of CTNNB1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; DKK1 protein inhibits the reaction [Berberine results in increased expression of SPP1 protein] |
CTD |
PMID:26478571 |
|
NCBI chr19:30,523,276...30,526,896
Ensembl chr19:30,523,263...30,527,065
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
decreases expression |
ISO |
Berberine results in decreased expression of DNMT1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 9:20,818,501...20,871,084
Ensembl chr 9:20,818,505...20,871,184
|
|
G |
Dnmt3b |
DNA methyltransferase 3B |
decreases expression |
ISO |
Berberine results in decreased expression of DNMT3B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:153,491,332...153,529,650
Ensembl chr 2:153,491,370...153,529,650
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein] |
CTD |
PMID:33325633 |
|
NCBI chr 3:129,471,223...129,548,971
Ensembl chr 3:129,471,214...129,548,965
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
ISO |
Berberine results in decreased expression of EGFR protein |
CTD |
PMID:33325633 |
|
NCBI chr11:16,700,153...16,868,158
Ensembl chr11:16,702,203...16,868,158
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
Berberine results in decreased phosphorylation of and results in increased expression of EIF4EBP1 protein |
CTD |
PMID:23363784 |
|
NCBI chr 8:27,750,355...27,765,684
Ensembl chr 8:27,750,357...27,766,702
|
|
G |
Ep300 |
E1A binding protein p300 |
increases expression |
ISO |
Berberine results in increased expression of EP300 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr15:81,470,329...81,536,273
Ensembl chr15:81,469,552...81,536,278
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Berberine results in decreased expression of ERBB2 protein]; Berberine results in decreased expression of and results in increased ubiquitination of ERBB2 protein |
CTD |
PMID:33325633 |
|
NCBI chr11:98,303,310...98,328,542
Ensembl chr11:98,303,296...98,328,542
|
|
G |
Esr1 |
estrogen receptor 1 (alpha) |
multiple interactions |
ISO |
Berberine inhibits the reaction [Estradiol results in increased activity of ESR1 protein] |
CTD |
PMID:30818834 |
|
NCBI chr10:4,561,989...4,955,633
Ensembl chr10:4,561,593...4,955,614
|
|
G |
Esrra |
estrogen related receptor, alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [XCT790 results in decreased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr19:6,888,345...6,899,182
Ensembl chr19:6,888,345...6,899,208
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression |
EXP ISO |
[Clozapine co-treated with Berberine] results in decreased expression of FAS mRNA; Berberine inhibits the reaction [Risperidone results in increased expression of FAS mRNA] Berberine results in increased expression of FAS mRNA; Berberine results in increased expression of FAS protein |
CTD |
PMID:20564506 PMID:20656010 |
|
NCBI chr19:34,267,926...34,305,175
Ensembl chr19:34,268,066...34,305,172
|
|
G |
Fasl |
Fas ligand |
increases expression |
ISO |
Berberine results in increased expression of FASLG mRNA; Berberine results in increased expression of FASLG protein |
CTD |
PMID:20656010 |
|
NCBI chr 1:161,608,260...161,616,064
Ensembl chr 1:161,608,258...161,616,064
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Thioacetamide results in increased expression of FN1 mRNA] Berberine inhibits the reaction [Particulate Matter results in increased expression of FN1 mRNA] |
CTD |
PMID:30138605 PMID:37839514 |
|
NCBI chr 1:71,624,632...71,692,439
Ensembl chr 1:71,624,679...71,692,359
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO1 protein; Berberine results in increased expression of and results in increased acetylation of FOXO1 protein |
CTD |
PMID:26712469 |
|
NCBI chr 3:52,175,758...52,257,530
Ensembl chr 3:52,175,757...52,260,642
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO3 protein; Berberine results in increased expression of and results in increased acetylation of FOXO3 protein |
CTD |
PMID:26712469 |
|
NCBI chr10:42,057,841...42,152,691
Ensembl chr10:42,057,837...42,152,751
|
|
G |
Fundc1 |
FUN14 domain containing 1 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of FUNDC1 protein [Cisplatin co-treated with Berberine] results in increased expression of FUNDC1 protein; FUNDC1 protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:36070022 |
|
NCBI chr X:17,386,206...17,438,600
Ensembl chr X:17,422,803...17,438,564
|
|
G |
Gata2 |
GATA binding protein 2 |
increases expression |
EXP |
Berberine results in increased expression of GATA2 mRNA |
CTD |
PMID:37511356 |
|
NCBI chr 6:88,170,873...88,184,014
Ensembl chr 6:88,170,873...88,184,014
|
|
G |
Gata3 |
GATA binding protein 3 |
increases expression |
EXP |
Berberine results in increased expression of GATA3 mRNA |
CTD |
PMID:37511356 |
|
NCBI chr 2:9,861,889...9,894,845
Ensembl chr 2:9,861,889...9,894,845
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
Berberine inhibits the reaction [Bortezomib results in increased expression of GCLC mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr 9:77,661,817...77,701,771
Ensembl chr 9:77,661,817...77,701,767
|
|
G |
Gclm |
glutamate-cysteine ligase, modifier subunit |
multiple interactions |
ISO |
Berberine inhibits the reaction [Bortezomib results in increased expression of GCLM mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381
|
|
G |
Gdf5 |
growth differentiation factor 5 |
decreases expression |
ISO |
Berberine results in decreased expression of GDF5 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 2:155,782,943...155,787,204
Ensembl chr 2:155,782,943...155,787,287
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
ISO |
Berberine inhibits the reaction [Bortezomib results in increased expression of GFAP mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr11:102,778,162...102,791,368
Ensembl chr11:102,778,162...102,791,738
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [Ethanol results in increased activity of GPT protein] Berberine inhibits the reaction [Mercuric Chloride results in increased activity of GPT protein]; Berberine inhibits the reaction [Thioacetamide results in increased activity of GPT protein] |
CTD |
PMID:24751971 PMID:25455889 PMID:30138605 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of GPX1 mRNA] |
CTD |
PMID:24751971 PMID:33460233 |
|
NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases phosphorylation |
EXP ISO |
Berberine inhibits the reaction [Dexamethasone results in decreased expression of GSK3B mRNA] Berberine results in increased phosphorylation of GSK3B protein Berberine inhibits the reaction [Glucose results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:20462044 PMID:23954465 |
|
NCBI chr16:37,909,363...38,066,446
Ensembl chr16:37,909,363...38,066,446
|
|
G |
Gsr |
glutathione reductase |
multiple interactions |
ISO |
Berberine inhibits the reaction [Chlorpyrifos results in decreased activity of GSR protein]; Berberine inhibits the reaction [Mercuric Chloride results in decreased activity of GSR protein] |
CTD |
PMID:24751971 PMID:25600690 PMID:33460233 PMID:35439518 |
|
NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191
|
|
G |
H2ac10 |
H2A clustered histone 10 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC14 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:23,718,045...23,718,548
Ensembl chr13:23,718,076...23,718,474
|
|
G |
H2ac12 |
H2A clustered histone 12 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC12 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:22,219,292...22,219,813
Ensembl chr13:22,219,334...22,219,738
|
|
G |
H2ac13 |
H2A clustered histone 13 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:21,900,582...21,901,029
Ensembl chr13:21,900,592...21,900,984
|
|
G |
H2ac18 |
H2A clustered histone 18 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC18 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 3:96,152,853...96,153,439
Ensembl chr 3:96,152,813...96,153,398
|
|
G |
H2ac22 |
H2A clustered histone 22 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC11 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:21,970,944...21,971,418
Ensembl chr13:21,970,996...21,971,388
|
|
G |
H2ac25 |
H2A clustered histone 25 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC25 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr11:58,845,511...58,846,018
Ensembl chr11:58,845,511...58,847,656
|
|
G |
H2ac4 |
H2A clustered histone 4 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC4 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:23,935,061...23,935,577
Ensembl chr13:23,935,109...23,935,581
|
|
G |
H2ac6 |
H2A clustered histone 6 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC15 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:23,867,456...23,867,942
Ensembl chr13:23,865,450...23,867,931
|
|
G |
H2ax |
H2A.X variant histone |
increases expression decreases expression multiple interactions |
ISO |
Berberine results in increased expression of H2AX protein modified form Berberine results in decreased expression of H2AX mRNA; Berberine results in decreased expression of H2AX protein TOP2A protein affects the reaction [Berberine results in increased expression of H2AX protein modified form] |
CTD |
PMID:23363784 PMID:23747414 PMID:27311644 |
|
NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374
|
|
G |
H2bc12 |
H2B clustered histone 12 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC12 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:22,219,991...22,220,490
Ensembl chr13:22,220,040...22,220,515
|
|
G |
H2bc14 |
H2B clustered histone 14 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:21,906,214...21,906,696
Ensembl chr13:21,906,214...21,906,737
|
|
G |
H2bc15 |
H2B clustered histone 15 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC15 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:21,938,246...21,938,723
Ensembl chr13:21,938,293...21,938,673
|
|
G |
H2bc21 |
H2B clustered histone 21 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC11 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 3:96,128,435...96,131,057
Ensembl chr 3:96,128,435...96,131,054
|
|
G |
H2bc22 |
H2B clustered histone 22 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC17 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:21,971,652...21,985,731
Ensembl chr13:21,971,631...21,973,383
|
|
G |
H2bc4 |
H2B clustered histone 4 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC4 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:23,868,182...23,876,805
Ensembl chr13:23,868,182...23,876,891
|
|
G |
H2bc6 |
H2B clustered histone 6 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:23,767,653...23,805,091
Ensembl chr13:23,767,653...23,805,107
|
|
G |
H2bc7 |
H2B clustered histone 7 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC13 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:23,757,934...23,758,381
Ensembl chr13:23,757,910...23,758,370
|
|
G |
H2bc8 |
H2B clustered histone 8 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:23,755,574...23,756,037
Ensembl chr13:23,755,570...23,756,187
|
|
G |
H2bc9 |
H2B clustered histone 9 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC9 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:23,727,093...23,727,614
Ensembl chr13:23,725,884...23,727,562
|
|
G |
H2bw2 |
H2B.W histone 2 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BW2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr X:135,828,074...135,829,122
Ensembl chr X:135,828,074...135,829,125
|
|
G |
H3c1 |
H3 clustered histone 1 |
decreases expression |
ISO |
Berberine results in decreased expression of H3C1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:23,945,868...23,946,369
Ensembl chr13:23,945,836...23,946,369
|
|
G |
H3c11 |
H3 clustered histone 11 |
decreases expression |
ISO |
Berberine results in decreased expression of H3C7 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:21,967,085...21,967,567
Ensembl chr13:21,967,130...21,967,540
|
|
G |
H3c8 |
H3 clustered histone 8 |
decreases expression |
ISO |
Berberine results in decreased expression of H3C12 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:23,719,588...23,720,079
Ensembl chr13:23,719,592...23,720,121
|
|
G |
H3f3a |
H3.3 histone A |
decreases expression |
ISO |
Berberine results in decreased expression of H3-3A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:180,630,125...180,641,127
Ensembl chr 1:180,628,397...180,641,508
|
|
G |
H3f4 |
H3.4 histone, cluster member |
decreases expression |
ISO |
Berberine results in decreased expression of H3-4 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr11:58,852,537...58,853,099
Ensembl chr11:58,852,599...58,853,364
|
|
G |
H4c12 |
H4 clustered histone 12 |
decreases expression |
ISO |
Berberine results in decreased expression of H4C8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:21,934,315...21,934,723
Ensembl chr13:21,934,364...21,934,675
|
|
G |
H4c14 |
H4 clustered histone 14 |
decreases expression |
ISO |
Berberine results in decreased expression of H4C3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 3:96,170,250...96,170,633
Ensembl chr 3:96,168,998...96,170,627
|
|
G |
H4c2 |
H4 clustered histone 2 |
decreases expression |
ISO |
Berberine results in decreased expression of H4C14 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:23,940,920...23,941,369
Ensembl chr13:23,940,996...23,941,392
|
|
G |
H4c8 |
H4 clustered histone 8 |
decreases expression |
ISO |
Berberine results in decreased expression of H4C9 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:23,715,214...23,715,648
Ensembl chr13:23,715,220...23,715,689
|
|
G |
Hat1 |
histone aminotransferase 1 |
increases expression |
ISO |
Berberine results in increased expression of HAT1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:71,219,604...71,271,966
Ensembl chr 2:71,219,302...71,271,966
|
|
G |
Hdac2 |
histone deacetylase 2 |
decreases expression |
ISO |
Berberine results in decreased expression of HDAC2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:36,850,293...36,877,885
Ensembl chr10:36,850,540...36,877,885
|
|
G |
Hdac5 |
histone deacetylase 5 |
increases expression |
ISO |
Berberine results in increased expression of HDAC5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr11:102,085,244...102,120,968
Ensembl chr11:102,085,258...102,120,992
|
|
G |
Hdac8 |
histone deacetylase 8 |
decreases expression |
ISO |
Berberine results in decreased expression of HDAC8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr X:101,328,244...101,549,005
Ensembl chr X:101,328,245...101,548,965
|
|
G |
Hdac9 |
histone deacetylase 9 |
decreases expression increases expression |
ISO |
Berberine results in decreased expression of HDAC9 mRNA Berberine results in increased expression of HDAC9 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr12:34,097,579...34,967,094
Ensembl chr12:34,097,579...34,967,094
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions increases expression |
ISO EXP |
15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of HGF mRNA]; 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of HGF protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Berberine results in increased expression of HGF protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of HGF mRNA]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of HGF protein]; Dactinomycin inhibits the reaction [Berberine results in increased expression of HGF protein]; PPARG mRNA promotes the reaction [Berberine results in increased expression of HGF protein] Berberine inhibits the reaction [Bleomycin results in decreased expression of HGF mRNA] Berberine results in increased expression of HGF mRNA; Berberine results in increased expression of HGF protein |
CTD |
PMID:29408570 |
|
NCBI chr 5:16,758,493...16,827,448
Ensembl chr 5:16,758,493...16,825,150
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of HMGB1 protein] |
CTD |
PMID:38705399 |
|
NCBI chr 5:148,983,512...148,989,867
Ensembl chr 5:148,983,512...149,121,299
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO EXP |
Berberine results in increased expression of HMOX1 protein Berberine results in increased expression of HMOX1 mRNA; Berberine results in increased expression of HMOX1 protein Berberine inhibits the reaction [Particulate Matter results in decreased expression of HMOX1 protein] Berberine inhibits the reaction [Bortezomib results in increased expression of HMOX1 mRNA] Berberine promotes the reaction [Glucose results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of HMOX1 protein] |
CTD |
PMID:23954465 PMID:35121005 PMID:37511356 PMID:37839514 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hnf4a |
hepatic nuclear factor 4, alpha |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Fructose results in decreased expression of HNF4A mRNA]; Berberine inhibits the reaction [Fructose results in decreased expression of HNF4A protein] Berberine inhibits the reaction [Ethanol results in decreased expression of HNF4 protein] |
CTD |
PMID:18563319 PMID:25455889 |
|
NCBI chr 2:163,348,731...163,414,827
Ensembl chr 2:163,348,728...163,414,830
|
|
G |
Idh3a |
isocitrate dehydrogenase 3 (NAD+) alpha |
decreases expression |
ISO |
Berberine results in decreased expression of IDH3A mRNA |
CTD |
PMID:30818834 |
|
NCBI chr 9:54,493,795...54,511,946
Ensembl chr 9:54,493,618...54,511,945
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Berberine inhibits the reaction [Thioacetamide results in increased expression of IFNG mRNA] |
CTD |
PMID:30138605 |
|
NCBI chr10:118,276,951...118,281,799
Ensembl chr10:118,276,951...118,281,797
|
|
G |
Igf1r |
insulin-like growth factor I receptor |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Glucose results in decreased expression of IGF1R protein] Berberine results in increased expression of IGF1R protein |
CTD |
PMID:23954465 |
|
NCBI chr 7:67,601,486...67,883,416
Ensembl chr 7:67,602,575...67,883,416
|
|
G |
Igf2bp3 |
insulin-like growth factor 2 mRNA binding protein 3 |
decreases expression multiple interactions |
ISO EXP |
Berberine results in decreased expression of IGF2BP3 protein Berberine inhibits the reaction [[Dextran Sulfate co-treated with azomethane] results in increased expression of IGF2BP3 protein] [Chloroquine co-treated with Berberine] results in decreased expression of IGF2BP3 protein; Berberine promotes the reaction [IGF2BP3 protein binds to TRIM21 protein]; Cycloheximide promotes the reaction [Berberine results in decreased expression of IGF2BP3 protein] |
CTD |
PMID:36822301 |
|
NCBI chr 6:49,062,152...49,200,225
Ensembl chr 6:49,062,157...49,191,891
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases expression |
EXP ISO |
Berberine affects the reaction [Lipopolysaccharides affects the expression of IL10 mRNA] [Berberine co-treated with Thioacetamide] results in increased expression of IL10 mRNA Berberine results in increased expression of IL10 mRNA |
CTD |
PMID:21867779 PMID:30138605 |
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein] Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B protein]; Berberine inhibits the reaction [Particulate Matter results in increased expression of IL1B protein] Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL1B mRNA] |
CTD |
PMID:16391493 PMID:29170048 PMID:30138605 PMID:35121005 PMID:35691465 PMID:37839514 PMID:38705399 More...
|
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il2 |
interleukin 2 |
increases expression |
EXP |
Berberine results in increased expression of IL2 mRNA |
CTD |
PMID:21867779 |
|
NCBI chr 3:37,174,862...37,180,103
Ensembl chr 3:37,174,672...37,180,108
|
|
G |
Il23a |
interleukin 23, alpha subunit p19 |
multiple interactions |
EXP |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL23A mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL23A protein] |
CTD |
PMID:30240693 |
|
NCBI chr10:128,132,009...128,133,953
Ensembl chr10:128,132,008...128,134,621
|
|
G |
Il4 |
interleukin 4 |
multiple interactions increases expression |
EXP |
Berberine inhibits the reaction [Lipopolysaccharides results in decreased expression of IL4 mRNA] Berberine results in increased expression of IL4 mRNA |
CTD |
PMID:21867779 |
|
NCBI chr11:53,503,287...53,509,492
Ensembl chr11:53,493,809...53,509,496
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL6 protein] Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL6 protein]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [Particulate Matter results in increased expression of IL6 protein] Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]; Berberine inhibits the reaction [Mustard Gas results in increased secretion of IL6 protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]] |
CTD |
PMID:28916288 PMID:29170048 PMID:30138605 PMID:30240693 PMID:34427876 PMID:35121005 PMID:35691465 PMID:37839514 PMID:38705399 More...
|
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Ins2 |
insulin II |
multiple interactions |
ISO |
[Berberine co-treated with Streptozocin] results in increased secretion of INS protein |
CTD |
PMID:15066220 |
|
NCBI chr 7:142,232,393...142,233,463
Ensembl chr 7:142,232,393...142,297,118
|
|
G |
Itga1 |
integrin alpha 1 |
increases expression |
ISO |
Berberine results in increased expression of ITGA1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr13:115,094,615...115,238,500
Ensembl chr13:115,089,632...115,238,500
|
|
G |
Itgb4 |
integrin beta 4 |
increases expression |
ISO |
berberine increases expression of ITGB4 protein in colon epithelial cells |
RGD |
PMID:29564000 |
RGD:152995489 |
NCBI chr11:115,865,556...115,899,238
Ensembl chr11:115,865,535...115,899,238
|
|
G |
Jun |
jun proto-oncogene |
affects localization multiple interactions |
ISO |
Berberine affects the localization of JUN protein arsenic trioxide promotes the reaction [Berberine affects the localization of JUN protein] |
CTD |
PMID:18294404 |
|
NCBI chr 4:94,937,273...94,940,459
Ensembl chr 4:94,937,271...94,940,459
|
|
G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
decreases activity multiple interactions |
ISO |
Berberine results in decreased activity of KCNH2 protein Berberine promotes the reaction [Atorvastatin results in decreased activity of KCNH2 protein]; Berberine promotes the reaction [Simvastatin results in decreased activity of KCNH2 protein] |
CTD |
PMID:30086269 |
|
NCBI chr 5:24,524,583...24,556,671
Ensembl chr 5:24,524,587...24,556,602
|
|
G |
Kdm4a |
lysine (K)-specific demethylase 4A |
increases expression |
ISO |
Berberine results in increased expression of KDM4A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 4:117,994,154...118,037,216
Ensembl chr 4:117,994,154...118,037,240
|
|
G |
Kdm5b |
lysine demethylase 5B |
increases expression |
ISO |
Berberine results in increased expression of KDM5B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:134,487,916...134,560,621
Ensembl chr 1:134,487,909...134,563,023
|
|
G |
Kdm6a |
lysine (K)-specific demethylase 6A |
increases expression |
ISO |
Berberine results in increased expression of KDM6A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr X:18,027,101...18,147,061
Ensembl chr X:18,028,814...18,146,175
|
|
G |
Kdm6b |
KDM1 lysine (K)-specific demethylase 6B |
increases expression |
ISO |
Berberine results in increased expression of KDM6B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr11:69,289,334...69,311,188
Ensembl chr11:69,289,334...69,304,501
|
|
G |
Kmt5a |
lysine methyltransferase 5A |
increases expression |
ISO |
Berberine results in increased expression of KMT5A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 5:124,577,980...124,600,371
Ensembl chr 5:124,577,993...124,600,371
|
|
G |
Kpna4 |
karyopherin subunit alpha 4 |
multiple interactions |
ISO |
Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of NFKBIA protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of RELA protein]]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]] |
CTD |
PMID:34427876 |
|
NCBI chr 3:68,979,554...69,034,425
Ensembl chr 3:68,974,482...69,034,446
|
|
G |
Lbpl |
lipid binding protein-like |
decreases expression increases expression multiple interactions |
ISO EXP |
Berberine results in decreased expression of FABP4 mRNA Berberine results in increased expression of FABP4 mRNA 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of FABP4 mRNA]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of FABP4 mRNA] |
CTD |
PMID:26478571 PMID:29408570 |
|
NCBI chr 3:10,269,406...10,273,653
Ensembl chr 3:10,269,148...10,273,636
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions increases expression |
EXP ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of LDLR mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of LDLR mRNA] Berberine results in increased expression of LDLR mRNA Berberine promotes the reaction [Simvastatin results in increased expression of LDLR mRNA]; Simvastatin promotes the reaction [Berberine results in increased expression of LDLR mRNA] |
CTD |
PMID:18640378 PMID:20564506 |
|
NCBI chr 9:21,634,872...21,661,215
Ensembl chr 9:21,634,779...21,661,215
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases localization |
ISO |
[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein; Berberine results in increased expression of and results in increased lipidation of MAP1LC3B protein; BNIP3L protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein]; FUNDC1 protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein] Berberine inhibits the reaction [Chlorpyrifos results in decreased expression of MAP1LC3B mRNA] Berberine results in increased localization of MAP1LC3B protein |
CTD |
PMID:35439518 PMID:36070022 |
|
NCBI chr 8:122,317,177...122,325,499
Ensembl chr 8:122,317,100...122,325,499
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
multiple interactions |
EXP |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in decreased expression of and results in increased phosphorylation of MAP3K5 protein] |
CTD |
PMID:30240693 |
|
NCBI chr10:19,809,847...20,018,496
Ensembl chr10:19,810,218...20,018,499
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
decreases phosphorylation |
ISO |
Berberine results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:18294404 |
|
NCBI chr16:16,801,246...16,865,317
Ensembl chr16:16,801,246...16,865,317
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
decreases phosphorylation multiple interactions |
ISO EXP |
Berberine results in decreased phosphorylation of MAPK3 protein Berberine inhibits the reaction [Dexamethasone results in decreased expression of MAPK3 mRNA] |
CTD |
PMID:18294404 PMID:20462044 |
|
NCBI chr 7:126,358,798...126,364,988
Ensembl chr 7:126,358,773...126,364,991
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[Berberine co-treated with Cisplatin] results in increased phosphorylation of MAPK8 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:36070022 |
|
NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
ISO |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA] |
CTD |
PMID:29170048 |
|
NCBI chr11:104,120,235...104,222,916
Ensembl chr11:104,122,216...104,222,916
|
|
G |
Mcm2 |
minichromosome maintenance complex component 2 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Dexamethasone results in increased expression of MCM2 mRNA] |
CTD |
PMID:20462044 |
|
NCBI chr 6:88,860,456...88,875,762
Ensembl chr 6:88,860,456...88,875,762
|
|
G |
Mir142 |
microRNA 142 |
multiple interactions |
ISO |
Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of MIR142 mRNA]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]] |
CTD |
PMID:34427876 |
|
NCBI chr11:87,647,690...87,647,753
Ensembl chr11:87,647,690...87,647,753
|
|
G |
Mir19a |
microRNA 19a |
decreases expression |
ISO |
Berberine results in decreased expression of MIR19A mRNA |
CTD |
PMID:29687521 |
|
NCBI chr14:115,281,432...115,281,513
Ensembl chr14:115,281,432...115,281,513
|
|
G |
Mir21a |
microRNA 21a |
decreases expression |
ISO |
berberine decreases expression of MIR21 RNA in colon epithelial cell |
RGD |
PMID:29564000 |
RGD:152995489 |
NCBI chr11:86,474,893...86,474,984
Ensembl chr11:86,474,893...86,474,984
|
|
G |
Mir92-1 |
microRNA 92-1 |
decreases expression |
ISO |
Berberine results in decreased expression of MIR92A1 mRNA |
CTD |
PMID:29687521 |
|
NCBI chr14:115,281,859...115,281,938
Ensembl chr14:115,281,859...115,281,938
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression |
ISO |
Berberine results in increased expression of MMP13 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 9:7,272,514...7,283,333
Ensembl chr 9:7,272,514...7,283,331
|
|
G |
Mmp14 |
matrix metallopeptidase 14 (membrane-inserted) |
multiple interactions decreases expression |
ISO |
arsenic trioxide promotes the reaction [Berberine results in decreased expression of MMP14 protein] |
CTD |
PMID:18294404 |
|
NCBI chr14:54,669,055...54,679,913
Ensembl chr14:54,669,069...54,682,821
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases activity decreases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]]; Arsenic Trioxide promotes the reaction [Berberine results in decreased activity of MMP2 protein]; Berberine promotes the reaction [Arsenic Trioxide results in decreased activity of MMP2 protein]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein] Berberine results in decreased expression of MMP2 protein arsenic trioxide promotes the reaction [Berberine results in decreased activity of MMP2 protein]; arsenic trioxide promotes the reaction [Berberine results in decreased expression of MMP2 protein]; Berberine promotes the reaction [arsenic trioxide results in decreased activity of MMP2 protein] |
CTD |
PMID:18294404 PMID:33325633 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases activity multiple interactions |
ISO |
Berberine results in decreased activity of MMP9 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein] |
CTD |
PMID:33325633 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of MPO protein] |
CTD |
PMID:21963898 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
mt-Co1 |
cytochrome c oxidase I, mitochondrial |
multiple interactions |
ISO |
Berberine inhibits the reaction [acetamiprid results in decreased expression of COX1 mRNA] |
CTD |
PMID:37350525 |
|
NCBI chr MT:5,328...6,872
Ensembl chr MT:5,328...6,872
|
|
G |
mt-Nd1 |
NADH dehydrogenase 1, mitochondrial |
multiple interactions |
ISO |
Berberine inhibits the reaction [acetamiprid results in decreased expression of ND1 mRNA] |
CTD |
PMID:37350525 |
|
NCBI chr MT:2,751...3,707
Ensembl chr MT:2,751...3,707
|
|
G |
mt-Nd2 |
NADH dehydrogenase 2, mitochondrial |
multiple interactions |
ISO |
Berberine inhibits the reaction [acetamiprid results in decreased expression of ND2 mRNA] |
CTD |
PMID:37350525 |
|
NCBI chr MT:3,914...4,951
Ensembl chr MT:3,914...4,951
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
Berberine inhibits the reaction [Chlorpyrifos results in increased expression of MTOR mRNA]; Berberine inhibits the reaction [Chlorpyrifos results in increased expression of MTOR protein] |
CTD |
PMID:35439518 |
|
NCBI chr 4:148,533,039...148,642,142
Ensembl chr 4:148,533,068...148,642,140
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions |
EXP |
Berberine inhibits the reaction [Ethanol results in decreased expression of MTTP protein] |
CTD |
PMID:25455889 |
|
NCBI chr 3:137,795,616...137,849,179
Ensembl chr 3:137,795,615...137,850,729
|
|
G |
Myc |
myelocytomatosis oncogene |
multiple interactions affects localization |
ISO |
arsenic trioxide promotes the reaction [Berberine affects the localization of MYC protein] |
CTD |
PMID:18294404 |
|
NCBI chr15:61,857,190...61,862,210
Ensembl chr15:61,857,240...61,862,223
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
multiple interactions decreases expression |
ISO |
[Berberine co-treated with Niacinamide] results in decreased expression of NAMPT protein; SRT1720 inhibits the reaction [Berberine results in decreased expression of NAMPT protein] |
CTD |
PMID:26712469 |
|
NCBI chr12:32,870,334...32,903,368
Ensembl chr12:32,869,544...32,903,348
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF1 protein] |
CTD |
PMID:36070022 |
|
NCBI chr 5:134,248,907...134,258,479
Ensembl chr 5:134,248,907...134,258,479
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
multiple interactions |
ISO |
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF2 protein] |
CTD |
PMID:36070022 |
|
NCBI chr 1:152,675,904...152,712,743
Ensembl chr 1:152,675,945...152,712,742
|
|
G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
increases expression multiple interactions increases activity |
ISO EXP |
Berberine results in increased expression of NFE2L2 protein Berberine inhibits the reaction [Particulate Matter results in decreased expression of NFE2L2 protein] Berberine results in increased activity of NFE2L2 protein Berberine inhibits the reaction [Bortezomib results in increased expression of NFE2L2 mRNA]; Berberine promotes the reaction [Bleomycin results in increased expression of NFE2L2 protein] NFE2L2 mutant form inhibits the reaction [Berberine inhibits the reaction [Glucose results in increased abundance of Reactive Oxygen Species]]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of NGF protein] |
CTD |
PMID:23523906 PMID:23954465 PMID:30818834 PMID:35121005 PMID:37839514 |
|
NCBI chr 2:75,505,860...75,535,007
Ensembl chr 2:75,505,857...75,534,985
|
|
G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Bortezomib results in increased expression of NFKB1 mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr 3:135,290,416...135,397,422
Ensembl chr 3:135,290,416...135,397,308
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of NFKBIA protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of NFKBIA protein]] |
CTD |
PMID:21963898 PMID:34427876 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
ISO |
Berberine inhibits the reaction [Glucose results in decreased expression of NGF protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of NGF protein] |
CTD |
PMID:23954465 |
|
NCBI chr 3:102,377,235...102,428,329
Ensembl chr 3:102,377,235...102,428,329
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Bortezomib results in increased expression of NLRP3 mRNA] Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 mRNA]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 protein] |
CTD |
PMID:35121005 PMID:38705399 |
|
NCBI chr11:59,432,395...59,457,781
Ensembl chr11:59,432,394...59,457,782
|
|
G |
Nos2 |
nitric oxide synthase 2, inducible |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein] Berberine inhibits the reaction [Bleomycin results in increased expression of NOS2 protein] |
CTD |
PMID:21095217 PMID:23523906 |
|
NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080
|
|
G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
multiple interactions |
ISO |
Berberine reverses reaction [Carbontetrachloride decreases Nqo1 mRNA in liver] Berberine inhibits the reaction [Bortezomib results in increased expression of NQO1 mRNA] |
CTD RGD |
PMID:35121005 PMID:31432116 |
RGD:25823187 |
NCBI chr 8:108,114,856...108,139,012
Ensembl chr 8:108,114,857...108,129,838
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
increases localization |
ISO |
Berberine increases localization of NR1H3 protein in macrophage nucleus |
RGD |
PMID:20506155 |
RGD:401827279 |
NCBI chr 2:91,014,406...91,033,189
Ensembl chr 2:91,014,406...91,033,179
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity multiple interactions |
ISO |
Berberine results in increased activity of NR1I2 protein [Berberine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:21524698 |
|
NCBI chr16:38,068,711...38,115,211
Ensembl chr16:38,068,685...38,115,186
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity |
ISO |
Berberine results in increased activity of NR1I3 protein |
CTD |
PMID:30818834 |
|
NCBI chr 1:171,041,503...171,046,414
Ensembl chr 1:171,041,539...171,048,270
|
|
G |
Odc1 |
ornithine decarboxylase, structural 1 |
multiple interactions decreases expression |
ISO |
arsenic trioxide promotes the reaction [Berberine results in decreased expression of ODC1 protein] |
CTD |
PMID:18294404 |
|
NCBI chr12:17,594,906...17,601,503
Ensembl chr12:17,594,795...17,601,506
|
|
G |
Omd |
osteomodulin |
increases expression |
ISO |
Berberine results in increased expression of OMD mRNA |
CTD |
PMID:26478571 |
|
NCBI chr13:49,735,938...49,746,088
Ensembl chr13:49,735,938...49,746,298
|
|
G |
P2rx7 |
purinergic receptor P2X, ligand-gated ion channel, 7 |
multiple interactions |
ISO |
Berberine affects the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] |
CTD |
PMID:21320518 |
|
NCBI chr 5:122,781,990...122,830,399
Ensembl chr 5:122,781,974...122,829,495
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
increases cleavage multiple interactions |
ISO |
Berberine results in increased cleavage of PARP1 protein [Berberine co-treated with Cisplatin] results in increased cleavage of PARP1 protein; [Berberine co-treated with Niacinamide] results in increased cleavage of PARP1 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased cleavage of PARP1 protein] |
CTD |
PMID:16505103 PMID:26712469 PMID:36070022 |
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase, isoenzyme 4 |
increases expression |
EXP |
Berberine results in increased expression of PDK4 mRNA |
CTD |
PMID:37511356 |
|
NCBI chr 6:5,483,351...5,496,278
Ensembl chr 6:5,483,351...5,496,309
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of PPARA mRNA] Berberine inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Dietary Carbohydrates] results in increased expression of PPARA protein] |
CTD |
PMID:18338635 PMID:25455889 |
|
NCBI chr15:85,619,112...85,691,052
Ensembl chr15:85,619,184...85,687,020
|
|
G |
Ppard |
peroxisome proliferator activator receptor delta |
increases activity multiple interactions increases expression |
EXP ISO |
Berberine results in increased activity of PPARD protein Berberine inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Dietary Carbohydrates] results in increased expression of PPARD protein] Berberine results in increased expression of PPARD mRNA; Berberine results in increased expression of PPARD protein |
CTD |
PMID:18338635 PMID:37511356 |
|
NCBI chr17:28,451,715...28,520,446
Ensembl chr17:28,451,674...28,520,448
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
multiple interactions decreases expression increases response to substance increases expression |
EXP ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of PPARG protein]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of PPARG mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG protein] Berberine inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Dietary Carbohydrates] results in decreased expression of PPARG protein] Berberine results in decreased expression of PPARG mRNA; Berberine results in decreased expression of PPARG protein 15-deoxyprostaglandin J2 promotes the reaction [Berberine affects the localization of and results in increased activity of PPARG protein]; Berberine inhibits the reaction [Bleomycin binds to PPARG protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 affects the localization of and results in increased activity of PPARG protein]; Berberine results in increased activity of and affects the localization of PPARG protein; PPARG mRNA promotes the reaction [Berberine results in increased expression of HGF protein] PPARG mRNA results in increased susceptibility to Berberine Berberine results in increased expression of PPARG mRNA |
CTD |
PMID:18338635 PMID:20564506 PMID:26478571 PMID:29408570 PMID:37511356 PMID:37839514 More...
|
|
NCBI chr 6:115,337,828...115,467,365
Ensembl chr 6:115,337,912...115,467,360
|
|
G |
Ppargc1a |
peroxisome proliferative activated receptor, gamma, coactivator 1 alpha |
multiple interactions |
EXP |
Berberine inhibits the reaction [Ethanol results in decreased expression of PPARGC1A mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr 5:51,611,591...52,273,316
Ensembl chr 5:51,611,592...51,725,068
|
|
G |
Prg4 |
proteoglycan 4 (megakaryocyte stimulating factor, articular superficial zone protein) |
decreases expression |
ISO |
Berberine results in decreased expression of PRG4 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 1:150,325,163...150,341,916
Ensembl chr 1:150,325,163...150,341,916
|
|
G |
Prkaa1 |
protein kinase, AMP-activated, alpha 1 catalytic subunit |
increases phosphorylation |
EXP |
Berberine results in increased phosphorylation of PRKAA1 protein |
CTD |
PMID:28298333 |
|
NCBI chr15:5,172,641...5,211,380
Ensembl chr15:5,173,343...5,211,380
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
ISO |
arsenic trioxide promotes the reaction [Berberine results in decreased activity of PRKCA protein]; Berberine results in decreased activity of and affects the localization of PRKCA protein |
CTD |
PMID:18294404 |
|
NCBI chr11:107,824,213...108,237,360
Ensembl chr11:107,824,213...108,234,754
|
|
G |
Prkce |
protein kinase C, epsilon |
multiple interactions decreases activity |
ISO |
arsenic trioxide promotes the reaction [Berberine results in decreased activity of PRKCE protein]; Berberine results in decreased activity of and affects the localization of PRKCE protein |
CTD |
PMID:18294404 |
|
NCBI chr17:86,472,631...86,965,347
Ensembl chr17:86,475,213...86,965,347
|
|
G |
Prmt1 |
protein arginine N-methyltransferase 1 |
decreases expression |
ISO |
Berberine results in decreased expression of PRMT1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 7:44,626,179...44,635,844
Ensembl chr 7:44,625,413...44,635,992
|
|
G |
Prmt2 |
protein arginine N-methyltransferase 2 |
increases expression |
ISO |
Berberine results in increased expression of PRMT2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:76,043,060...76,073,699
Ensembl chr10:76,043,056...76,073,699
|
|
G |
Prmt5 |
protein arginine N-methyltransferase 5 |
increases expression |
ISO |
Berberine results in increased expression of PRMT5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr14:54,744,639...54,754,927
Ensembl chr14:54,744,644...54,754,982
|
|
G |
Prmt6 |
protein arginine N-methyltransferase 6 |
increases expression |
ISO |
Berberine results in increased expression of PRMT6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 3:110,153,420...110,158,315
Ensembl chr 3:110,153,425...110,158,314
|
|
G |
Prmt7 |
protein arginine N-methyltransferase 7 |
increases expression |
ISO |
Berberine results in increased expression of PRMT7 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 8:106,937,686...106,978,326
Ensembl chr 8:106,937,568...106,979,426
|
|
G |
Prmt8 |
protein arginine N-methyltransferase 8 |
increases expression |
ISO |
Berberine results in increased expression of PRMT8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:127,665,972...127,746,430
Ensembl chr 6:127,665,974...127,746,435
|
|
G |
Pten |
phosphatase and tensin homolog |
increases expression multiple interactions |
EXP |
Berberine results in increased expression of PTEN protein ((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide) inhibits the reaction [Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN mRNA]]; Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN mRNA]; Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN protein] |
CTD |
PMID:29408570 |
|
NCBI chr19:32,734,977...32,803,560
Ensembl chr19:32,734,897...32,803,560
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein] |
CTD |
PMID:21095217 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of PYCARD mRNA] |
CTD |
PMID:38705399 |
|
NCBI chr 7:127,590,545...127,593,039
Ensembl chr 7:127,588,880...127,593,039
|
|
G |
Rac2 |
Rac family small GTPase 2 |
multiple interactions |
ISO |
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to RAC2 protein]; Berberine results in increased expression of and results in increased activity of RAC2 protein |
CTD |
PMID:36070022 |
|
NCBI chr15:78,443,369...78,456,983
Ensembl chr15:78,443,367...78,456,983
|
|
G |
Rbp4 |
retinol binding protein 4, plasma |
multiple interactions |
ISO |
Berberine inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased secretion of RBP4 protein] |
CTD |
PMID:19080170 |
|
NCBI chr19:38,105,068...38,113,769
Ensembl chr19:38,105,077...38,113,729
|
|
G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
multiple interactions |
ISO |
Berberine inhibits the reaction [Bleomycin affects the localization of and results in increased expression of RELA protein] Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of RELA protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of RELA protein]] |
CTD |
PMID:23523906 PMID:34427876 |
|
NCBI chr19:5,686,993...5,698,162
Ensembl chr19:5,687,511...5,698,158
|
|
G |
Rln1 |
relaxin 1 |
affects binding increases expression multiple interactions |
ISO |
Berberine binds to RLN1 promoter Berberine results in increased expression of RLN1 mRNA [Berberine binds to RLN1 promoter] which results in increased expression of RLN1 mRNA |
CTD |
PMID:22363579 |
|
NCBI chr19:29,309,155...29,312,070
Ensembl chr19:29,308,570...29,312,070
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation |
ISO |
Berberine results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:23363784 |
|
NCBI chr 4:86,772,336...86,775,604
Ensembl chr 4:86,772,897...86,775,649
|
|
G |
Runx2 |
runt related transcription factor 2 |
multiple interactions increases expression |
ISO |
CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; DKK1 protein inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA] |
CTD |
PMID:26478571 |
|
NCBI chr17:44,806,873...45,125,518
Ensembl chr17:44,806,874...45,125,684
|
|
G |
Setd1b |
SET domain containing 1B |
increases expression |
ISO |
Berberine results in increased expression of SETD1B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 5:123,280,109...123,306,693
Ensembl chr 5:123,280,256...123,306,692
|
|
G |
Setd3 |
SET domain containing 3 |
increases expression |
ISO |
Berberine results in increased expression of SETD3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr12:108,072,690...108,145,616
Ensembl chr12:108,072,690...108,145,573
|
|
G |
Setd5 |
SET domain containing 5 |
increases expression |
ISO |
Berberine results in increased expression of SETD5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:113,054,326...113,130,393
Ensembl chr 6:113,054,326...113,130,396
|
|
G |
Setd6 |
SET domain containing 6 |
increases expression |
ISO |
Berberine results in increased expression of SETD6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 8:96,442,211...96,448,135
Ensembl chr 8:96,442,509...96,445,638
|
|
G |
Setd7 |
SET domain containing (lysine methyltransferase) 7 |
increases expression |
ISO |
Berberine results in increased expression of SETD7 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 3:51,422,740...51,468,519
Ensembl chr 3:51,422,740...51,468,300
|
|
G |
Setdb1 |
SET domain, bifurcated 1 |
increases expression |
ISO |
Berberine results in increased expression of SETDB1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 3:95,230,836...95,264,513
Ensembl chr 3:95,230,836...95,264,513
|
|
G |
Setdb2 |
SET domain, bifurcated 2 |
increases expression |
ISO |
Berberine results in increased expression of SETDB2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr14:59,639,458...59,678,329
Ensembl chr14:59,639,458...59,678,333
|
|
G |
Sirt1 |
sirtuin 1 |
decreases expression multiple interactions |
ISO |
Berberine results in decreased expression of SIRT1 mRNA; Berberine results in decreased expression of SIRT1 protein Berberine inhibits the reaction [Bortezomib results in decreased expression of SIRT1 protein] [Berberine co-treated with Niacinamide] results in decreased expression of SIRT1 protein; SRT1720 inhibits the reaction [Berberine results in decreased expression of SIRT1 protein] |
CTD |
PMID:26712469 PMID:35121005 |
|
NCBI chr10:63,154,784...63,174,814
Ensembl chr10:63,154,784...63,217,483
|
|
G |
Sirt2 |
sirtuin 2 |
multiple interactions |
ISO |
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT2 protein |
CTD |
PMID:26712469 |
|
NCBI chr 7:28,466,192...28,488,086
Ensembl chr 7:28,466,160...28,488,086
|
|
G |
Sirt3 |
sirtuin 3 |
multiple interactions increases expression decreases expression |
ISO |
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT3 protein Berberine results in increased expression of SIRT3 mRNA Berberine results in decreased expression of SIRT3 mRNA; Berberine results in decreased expression of SIRT3 protein |
CTD |
PMID:26712469 PMID:27311644 |
|
NCBI chr 7:140,443,576...140,462,222
Ensembl chr 7:140,443,579...140,462,222
|
|
G |
Sis |
sucrase isomaltase |
decreases expression multiple interactions |
ISO |
Berberine results in decreased expression of SI mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Berberine results in decreased expression of SI mRNA] |
CTD |
PMID:20229011 |
|
NCBI chr 3:72,795,890...72,875,196
Ensembl chr 3:72,795,890...72,875,196
|
|
G |
Slc27a5 |
solute carrier family 27 (fatty acid transporter), member 5 |
decreases expression |
ISO |
Berberine results in decreased expression of SLC27A5 mRNA |
CTD |
PMID:28038998 |
|
NCBI chr 7:12,722,273...12,732,119
Ensembl chr 7:12,722,273...12,732,119
|
|
G |
Slc2a4 |
solute carrier family 2 (facilitated glucose transporter), member 4 |
multiple interactions |
ISO |
Berberine inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of SLC2A4 protein] |
CTD |
PMID:19080170 |
|
NCBI chr11:69,833,112...69,839,040
Ensembl chr11:69,833,365...69,839,014
|
|
G |
Slc6a19 |
solute carrier family 6 (neurotransmitter transporter), member 19 |
multiple interactions |
ISO |
Berberine affects the reaction [Lipopolysaccharides affects the expression of SLC6A19 mRNA]; Berberine affects the reaction [Lipopolysaccharides affects the expression of SLC6A19 protein] |
CTD |
PMID:21073932 |
|
NCBI chr13:73,827,864...73,848,899
Ensembl chr13:73,827,864...73,852,984
|
|
G |
Smyd3 |
SET and MYND domain containing 3 |
affects expression |
ISO |
Berberine affects the expression of SMYD3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:178,779,525...179,345,618
Ensembl chr 1:178,779,525...179,345,606
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Particulate Matter results in decreased expression of SOCS3 mRNA]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of SOCS3 protein] |
CTD |
PMID:37839514 |
|
NCBI chr11:117,856,905...117,860,192
Ensembl chr11:117,856,905...117,860,873
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [Carbon Tetrachloride results in decreased activity of SOD1 protein]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of SOD1 protein]; Berberine inhibits the reaction [Streptozocin affects the expression of SOD1 mRNA] Berberine inhibits the reaction [Chlorpyrifos results in decreased activity of SOD1 protein] |
CTD |
PMID:21095217 PMID:22775417 PMID:35439518 PMID:37839514 |
|
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [Streptozocin affects the expression of SOD2 mRNA] Berberine inhibits the reaction [acetamiprid results in decreased expression of SOD2 mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of SOD2 mRNA] |
CTD |
PMID:22775417 PMID:24751971 PMID:33460233 PMID:37350525 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Sox9 |
SRY (sex determining region Y)-box 9 |
decreases expression |
ISO |
Berberine results in decreased expression of SOX9 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr11:112,673,036...112,678,583
Ensembl chr11:112,673,050...112,678,586
|
|
G |
Sp7 |
Sp7 transcription factor 7 |
increases expression |
ISO |
Berberine results in increased expression of SP7 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr15:102,265,038...102,275,498
Ensembl chr15:102,265,041...102,275,617
|
|
G |
Sparc |
secreted acidic cysteine rich glycoprotein |
increases expression |
ISO |
Berberine results in increased expression of SPARC mRNA |
CTD |
PMID:26478571 |
|
NCBI chr11:55,284,985...55,310,906
Ensembl chr11:55,285,326...55,314,009
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of SPP1 mRNA; Berberine results in increased expression of SPP1 protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of SPP1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of SPP1 protein] |
CTD |
PMID:26478571 |
|
NCBI chr 5:104,582,977...104,588,919
Ensembl chr 5:104,582,984...104,588,916
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression multiple interactions |
ISO EXP |
Berberine results in increased expression of SQSTM1 protein [Berberine co-treated with Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of SQSTM1 protein |
CTD |
PMID:36070022 PMID:38705399 |
|
NCBI chr11:50,090,979...50,105,303
Ensembl chr11:50,090,193...50,101,654
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions decreases expression |
EXP ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of SREBF1 protein]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 protein] Berberine results in decreased expression of SREBF1 mRNA |
CTD |
PMID:20564506 PMID:26478571 |
|
NCBI chr11:60,089,910...60,113,407
Ensembl chr11:60,089,915...60,113,407
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Bortezomib results in increased expression of STAT3 mRNA] Berberine inhibits the reaction [Particulate Matter results in increased expression of STAT3 mRNA] |
CTD |
PMID:35121005 PMID:37839514 |
|
NCBI chr11:100,777,632...100,830,447
Ensembl chr11:100,775,924...100,830,366
|
|
G |
Tert |
telomerase reverse transcriptase |
decreases activity |
ISO |
Berberine results in decreased activity of TERT protein |
CTD |
PMID:25265580 |
|
NCBI chr13:73,775,030...73,797,962
Ensembl chr13:73,775,030...73,797,962
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases expression multiple interactions |
ISO EXP |
Berberine results in decreased expression of TGFB1 protein Berberine inhibits the reaction [Particulate Matter results in increased expression of TGFB1 mRNA] Berberine inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of TGFB1 mRNA] |
CTD |
PMID:17973934 PMID:23523906 PMID:30138605 PMID:37839514 |
|
NCBI chr 7:25,386,406...25,404,503
Ensembl chr 7:25,386,427...25,404,502
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TLR4 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TLR4 protein]; Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 mRNA] Berberine inhibits the reaction [Bortezomib results in increased expression of TLR4 protein] |
CTD |
PMID:21963898 PMID:30240693 PMID:35121005 |
|
NCBI chr 4:66,745,788...66,765,338
Ensembl chr 4:66,745,821...66,848,521
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion increases expression |
ISO EXP |
Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]; Berberine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]] Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein]; Berberine inhibits the reaction [Bleomycin results in increased expression of TNF protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of TNF protein] Berberine results in increased secretion of TNF protein Berberine results in increased expression of TNF mRNA Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in decreased expression of and results in increased phosphorylation of MAP3K5 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL23A mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TLR4 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TRAF2 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL23A protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL6 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TLR4 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Benzo(a)pyrene results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Berberine inhibits the reaction [Dietary Fats results in increased secretion of TNF protein]; Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Particulate Matter results in increased expression of TNF protein] |
CTD |
PMID:16391493 PMID:20656010 PMID:21095217 PMID:21867779 PMID:23523906 PMID:25600690 PMID:28533128 PMID:29170048 PMID:30240693 PMID:34427876 PMID:35121005 PMID:35691465 PMID:37511356 PMID:37839514 PMID:38705399 More...
|
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
G |
Top1 |
topoisomerase (DNA) I |
decreases activity |
ISO |
Berberine results in decreased activity of TOP1 protein |
CTD |
PMID:23747414 |
|
NCBI chr 2:160,487,901...160,564,684
Ensembl chr 2:160,487,808...160,564,684
|
|
G |
Top2a |
topoisomerase (DNA) II alpha |
multiple interactions affects response to substance |
ISO |
TOP2A protein affects the reaction [Berberine results in increased expression of H2AX protein modified form] TOP2A protein affects the susceptibility to Berberine |
CTD |
PMID:23747414 |
|
NCBI chr11:98,883,773...98,915,037
Ensembl chr11:98,883,769...98,915,015
|
|
G |
Traf1 |
TNF receptor-associated factor 1 |
increases expression |
ISO |
Berberine results in increased expression of TRAF1 protein |
CTD |
PMID:20656010 |
|
NCBI chr 2:34,831,762...34,851,784
Ensembl chr 2:34,831,762...34,851,784
|
|
G |
Traf2 |
TNF receptor-associated factor 2 |
multiple interactions |
EXP |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TRAF2 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein] |
CTD |
PMID:30240693 |
|
NCBI chr 2:25,407,994...25,436,952
Ensembl chr 2:25,407,994...25,436,952
|
|
G |
Trim21 |
tripartite motif-containing 21 |
multiple interactions |
ISO |
Berberine promotes the reaction [IGF2BP3 protein binds to TRIM21 protein] |
CTD |
PMID:36822301 |
|
NCBI chr 7:102,207,127...102,214,689
Ensembl chr 7:102,207,128...102,214,693
|
|
G |
Trp53 |
transformation related protein 53 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of TP53 mRNA; Berberine results in increased expression of TP53 protein [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of TP53 protein; Berberine results in increased phosphorylation of and results in increased acetylation of TP53 protein |
CTD |
PMID:20656010 PMID:26712469 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Tstd1 |
thiosulfate sulfurtransferase (rhodanese)-like domain containing 1 |
increases expression |
ISO |
Berberine results in increased expression of TSTD1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:171,246,601...171,247,920
Ensembl chr 1:171,246,440...171,247,920
|
|
G |
Ube2a |
ubiquitin-conjugating enzyme E2A |
decreases expression |
ISO |
Berberine results in decreased expression of UBE2A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr X:36,137,948...36,147,875
Ensembl chr X:36,064,828...36,147,875
|
|
G |
Ube2b |
ubiquitin-conjugating enzyme E2B |
decreases expression |
ISO |
Berberine results in decreased expression of UBE2B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr11:51,875,965...51,894,972
Ensembl chr11:51,876,324...51,891,589
|
|
G |
Ucp2 |
uncoupling protein 2 (mitochondrial, proton carrier) |
multiple interactions increases expression |
EXP |
Berberine inhibits the reaction [Benzo(a)pyrene results in increased expression of UCP2 mRNA] Berberine results in increased expression of UCP2 mRNA |
CTD |
PMID:28533128 PMID:37511356 |
|
NCBI chr 7:100,142,565...100,148,832
Ensembl chr 7:100,142,544...100,151,227
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Berberine results in decreased expression of VEGFA protein |
CTD |
PMID:33325633 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
G |
Vegfc |
vascular endothelial growth factor C |
increases expression |
ISO |
Berberine results in increased expression of VEGFC mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 8:54,530,567...54,639,489
Ensembl chr 8:54,530,641...54,640,131
|
|
G |
Whsc1l |
Wolf-Hirschhorn syndrome candidate 1-like |
decreases expression |
ISO |
Berberine results in decreased expression of NSD2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 5:33,974,286...34,055,310
Ensembl chr 5:33,978,069...34,055,319
|
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
manoalide inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:7575673 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
manoalide inhibits the reaction [[Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; manoalide inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] |
CTD |
PMID:7575673 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
manoalide inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:7575673 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
4-amylcinnamoylanthranilic acid inhibits the reaction [Buthionine Sulfoximine results in increased activity of CASP3 protein] 4-amylcinnamoylanthranilic acid inhibits the reaction [Eicosapentaenoic Acid promotes the reaction [Cisplatin results in increased activity of CASP3 protein]] |
CTD |
PMID:33309544 PMID:35395232 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
4-amylcinnamoylanthranilic acid inhibits the reaction [Eicosapentaenoic Acid promotes the reaction [Cisplatin results in increased activity of CASP8 protein]] |
CTD |
PMID:35395232 |
|
NCBI chr 1:58,834,553...58,886,663
Ensembl chr 1:58,834,533...58,886,662
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP ISO |
4-amylcinnamoylanthranilic acid inhibits the reaction [Buthionine Sulfoximine results in increased activity of CASP9 protein] 4-amylcinnamoylanthranilic acid inhibits the reaction [Eicosapentaenoic Acid promotes the reaction [Cisplatin results in increased activity of CASP9 protein]] |
CTD |
PMID:33309544 PMID:35395232 |
|
NCBI chr 4:141,520,923...141,543,289
Ensembl chr 4:141,520,923...141,543,287
|
|
G |
Slc13a2 |
solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 2 |
multiple interactions |
ISO |
[4-amylcinnamoylanthranilic acid results in decreased activity of SLC13A2 protein] which results in decreased susceptibility to diethylene glycol metabolite |
CTD |
PMID:21856646 |
|
NCBI chr11:78,288,102...78,313,107
Ensembl chr11:78,287,913...78,313,043
|
|
G |
Trpm2 |
transient receptor potential cation channel, subfamily M, member 2 |
multiple interactions decreases activity |
ISO EXP |
4-amylcinnamoylanthranilic acid inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Eicosapentaenoic Acid promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Eicosapentaenoic Acid promotes the reaction [Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]] 4-amylcinnamoylanthranilic acid results in decreased activity of TRPM2 protein 4-amylcinnamoylanthranilic acid inhibits the reaction [[Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein] |
CTD |
PMID:18204483 PMID:30229906 PMID:33309544 PMID:34958835 PMID:35395232 |
|
NCBI chr10:77,743,556...77,805,746
Ensembl chr10:77,743,556...77,806,397
|
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
scalaradial inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; scalaradial inhibits the reaction [IL1B protein results in increased expression of TNF protein]; scalaradial inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:7575673 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
scalaradial inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MPO protein] |
CTD |
PMID:8113982 |
|
NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
scalaradial inhibits the reaction [[Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; scalaradial inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; scalaradial inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] |
CTD |
PMID:7575673 |
|
NCBI chr 1:149,975,851...149,983,978
Ensembl chr 1:149,975,782...149,983,978
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
scalaradial inhibits the reaction [IL1B protein results in increased expression of TNF protein]; scalaradial inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:7575673 |
|
NCBI chr17:35,418,343...35,420,983
Ensembl chr17:35,418,357...35,420,983
|
|
|
G |
F10 |
coagulation factor X |
multiple interactions |
ISO |
varespladib inhibits the reaction [micrurus venom results in decreased activity of F10 protein] |
CTD |
PMID:33197555 |
|
NCBI chr 8:13,087,308...13,106,676
Ensembl chr 8:13,087,308...13,106,676
|
|
G |
Gpt |
glutamic pyruvic transaminase, soluble |
multiple interactions |
ISO |
[Antivenins co-treated with varespladib] inhibits the reaction [micrurus venom results in increased expression of GPT protein] |
CTD |
PMID:34774704 |
|
NCBI chr15:76,580,926...76,583,875
Ensembl chr15:76,579,916...76,583,886
|
|
G |
Pla2g2a |
phospholipase A2, group IIA (platelets, synovial fluid) |
decreases activity multiple interactions |
ISO |
varespladib results in decreased activity of PLA2G2A protein varespladib inhibits the reaction [PLA2G2A protein results in increased abundance of Thromboxane A2 metabolite]; varespladib inhibits the reaction [PLA2G2A protein results in increased abundance of Thromboxane B2] |
CTD |
PMID:10027849 |
|
NCBI chr 4:138,559,168...138,562,500
Ensembl chr 4:138,559,171...138,562,497
|
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
varespladib methyl inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; varespladib methyl inhibits the reaction [IL1B protein results in increased expression of MMP2 mRNA]; varespladib methyl inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; varespladib methyl inhibits the reaction [IL1B protein results in increased expression of MMP9 mRNA]; varespladib methyl inhibits the reaction [IL1B protein results in increased secretion of MMP1 protein]; varespladib methyl inhibits the reaction [IL1B protein results in increased secretion of MMP2 protein]; varespladib methyl inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein]; varespladib methyl inhibits the reaction [IL1B protein results in increased secretion of MMP9 protein]; varespladib methyl inhibits the reaction [IL1B protein results in increased secretion of PLA2G2A protein] |
CTD |
PMID:19765281 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Mmp1b |
matrix metallopeptidase 1b (interstitial collagenase) |
multiple interactions |
ISO |
varespladib methyl inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; varespladib methyl inhibits the reaction [IL1B protein results in increased secretion of MMP1 protein] |
CTD |
PMID:19765281 |
|
NCBI chr 9:7,367,670...7,388,026
Ensembl chr 9:7,368,239...7,388,047
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
varespladib methyl inhibits the reaction [IL1B protein results in increased expression of MMP2 mRNA]; varespladib methyl inhibits the reaction [IL1B protein results in increased secretion of MMP2 protein] |
CTD |
PMID:19765281 |
|
NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions |
ISO |
varespladib methyl inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; varespladib methyl inhibits the reaction [IL1B protein results in increased secretion of MMP3 protein] |
CTD |
PMID:19765281 |
|
NCBI chr 9:7,445,845...7,455,975
Ensembl chr 9:7,445,822...7,455,975
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
varespladib methyl inhibits the reaction [IL1B protein results in increased expression of MMP9 mRNA]; varespladib methyl inhibits the reaction [IL1B protein results in increased secretion of MMP9 protein] |
CTD |
PMID:19765281 |
|
NCBI chr 2:164,782,246...164,797,770
Ensembl chr 2:164,782,700...164,797,770
|
|
G |
Pla2g2a |
phospholipase A2, group IIA (platelets, synovial fluid) |
multiple interactions |
ISO |
varespladib methyl inhibits the reaction [IL1B protein results in increased secretion of PLA2G2A protein] |
CTD |
PMID:19765281 |
|
NCBI chr 4:138,559,168...138,562,500
Ensembl chr 4:138,559,171...138,562,497
|
|